Description
ULTOMIRIS is a complement inhibitor indicated for:
• The treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). The treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit
complement-mediated thrombotic microangiopathy (TMA).
Limitations of Use:
ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
• The treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.
• The treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive.
Additional information
| Brand | ULTOMIRIS® |
|---|---|
| Generic name | Ravulizumab-cwvz for injection |
| Form | Parenteral |
| Strength | 300mg/3mL |
| Manufacturer | Alexion Pharmaceuticals |
| Documents | Either PO or prescription |
| Storage | 2-8°C temperature |
Reviews
There are no reviews yet.